ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Brose on the FACT2 Study and the Treatment of ATC

Marcia S. Brose, MD, PhD
Published: Friday, Jan 24, 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.

ATC is a devastating disease, Brose says, and there remains a need for agents that are effective. It may be possible to combine targeted agents, as some have demonstrated limited activity.

Outside the U.S., there is a push to move forward with the FACT2 study, which aims to analyze the efficacy of fosbretabulin given with chemotherapy (paclitaxel and carboplatin). Brose hopes that the results will have an impact on the treatment of ATC in the U.S.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.

ATC is a devastating disease, Brose says, and there remains a need for agents that are effective. It may be possible to combine targeted agents, as some have demonstrated limited activity.

Outside the U.S., there is a push to move forward with the FACT2 study, which aims to analyze the efficacy of fosbretabulin given with chemotherapy (paclitaxel and carboplatin). Brose hopes that the results will have an impact on the treatment of ATC in the U.S.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x